The application of a new-type bioreactor in the ex vivo expansion of hematopoietic stem/progenitor cells.
- Author:
Meiqin ZHOU
1
;
Haibo CAI
;
Wensong TAN
Author Information
1. State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China.
- Publication Type:Journal Article
- MeSH:
Antigens, CD34;
metabolism;
Bioreactors;
Cell Culture Techniques;
methods;
Cell Differentiation;
physiology;
Cell Proliferation;
Cytokines;
pharmacology;
Fetal Blood;
cytology;
Hematopoietic Stem Cells;
cytology;
immunology;
Humans;
Stem Cell Factor;
pharmacology
- From:
Chinese Journal of Biotechnology
2008;24(5):786-792
- CountryChina
- Language:Chinese
-
Abstract:
Based on the requirement of culture conditions for hematopoietic stem and progenitor cells (HSPCs) ex vive expansion, we developed a new-type bioreactor by combining superiorities of static and stirred culture models. Stem cell factor (SCF), thrombopoietin (TPO), FLT-3 ligand(Flt-3) were used as the cytokines cocktails. The effects of the static and cyclic culture on the expansion characteristics of CD34+ selected cells were compared in the new-type bioreactor. After 7 d cultures, the expansion of total cells in the static culture was 13.86 +/- 4.26 fold, higher than that in the cyclic culture (7.23 +/- 2.67 fold). The analysis of the fold expansion and the proportion of CD34+ cells showed that there was no marked difference between the static culture and the cyclic culture. However, the fold expansion and the proportion of CD34+CD38- cells were higher in the cyclic culture than those in the static culture (3.90 +/- 0.85 versus 1.82 +/- 0.58), which reflected more primary CD34+CD38- cells were obtained in the cyclic culture. The above results demonstrated that both the static culture and the cyclic culture could be used in ex vive expansion of CD34+ cells with the new-type bioreactor. In static culture hematopoietic stem cells differentiated into progenitor cells, whilst the cyclic culture favored the expansion of primary HSPCs.
